Aurobindo Pharma Q4 Results
- BSE: 524804
- NSE: AUROPHARMA
- ISIN: INE406A01037
- Sector: Major Drugs
BSE
1,477.50
13.40 (0.92%)
13.40 (0.92%)Volume11.33 K
Updated: Fri 12 Jun, 2026 | 11:12:02
NSE
1,477.1013.00 (0.89%)
13.00 (0.89%)Volume2.41 L
Updated: Fri 12 Jun, 2026 | 10:57:05
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹8,853.34 Cr.(5.62%)
- Operating Profit₹1,322.37 Cr.(-0.19%)
- Profit After Tax₹921.26 Cr.(1.97%)
- Operating Margin14.94%(-5.50%)
Note: Comparison is on YoY basis
Quarterly - Aurobindo Pharma Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 7,530.97 | 7,402.62 | 1.73% | 6,369.50 | 6.71% |
| Depreciation/ Amortization | 478.57 | 464.73 | 2.98% | 354.33 | 7.68% |
| Operating Income | 1,322.37 | 1,243.28 | 6.36% | 1,210.65 | -0.19% |
| Net Income | 921.26 | 910.29 | 1.21% | 908.75 | 1.97% |
| Other Operating Expenses Total | 2,249.35 | 2,081.29 | 8.07% | 1,805.86 | 11.23% |
| Net Income Before Taxes | 1,290.61 | 1,338.52 | -3.58% | 1,229.90 | -3.33% |
| Total Revenue | 8,853.34 | 8,645.90 | 2.40% | 7,580.15 | 5.62% |
| Selling/ General/ Admin Expenses Total | 1,373.98 | 1,310.06 | 4.88% | 1,026.32 | 18.18% |
| Diluted Normalized EPS | 15.86 | 16.43 | -3.50% | 17.10 | 1.94% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.